Wells Fargo cuts Globe Life stock price target on health unit pressure
Wells Fargo reduced its price target for Globe Life (NYSE:GL) to $180 from $191, citing expected pressure on health unit earnings. The firm lowered EPS estimates due to challenges in health underwriting and elevated Medicare Supplement claims. Globe Life shares fell 8% on Friday. The company reported Q3 2026 net operating income of $4.84 per diluted share, missing estimates, despite revenue growth. Piper Sandler downgraded GL to Neutral with a $165 price target, citing medical claims volatility.
How this was made
The 30-second read
Why it matters
The downgrade reflects concerns over rising Medicare Supplement claims and health underwriting loss ratios, which could pressure the stock further.
Market read
Analyst downgrade after earnings miss may trigger short-term sell pressure on GL and influence sector sentiment.
What to watch
Potential upside from Medicare Supplement pricing improvements in Q2 2027.
Background
Globe Life reported Q3 2026 results that missed EPS expectations despite revenue beat, prompting analyst scrutiny of its health segment.
Ticker impact
Wells Fargo lowered GL's price target to $180 and cut EPS estimates due to pressure on its health unit, following a Q3 earnings miss.
likely downward pressure as investors price in weaker health segment outlook
Target cut and EPS downgrade directly follow earnings miss, prompting sell-side sentiment shift.
Market effects
Health insurance underwriting pressure may affect peers in the life insurance sector.
U.S. insurers could see broader valuation adjustments.
Limited to U.S. market; no global macro impact.
Counterpoint
If health unit losses are temporary, the stock may be oversold after the downgrade.
Key entities
- companyGlobe Life
U.S. life insurer (NYSE:GL) facing health unit pressure.
- analystWells Fargo
Equity research firm that cut GL's price target and EPS forecast.
